What are the best treatments for Megalencephaly Capillary Malformation Polymicrogyria Syndrome (mcap)?

TL;DR: There is no singular cure for Megalencephaly Capillary Malformation Polymicrogyria Syndrome (MCAP), so treatment is strictly multidisciplinary and focuses on managing specific symptoms like seizures, developmental delays, and overgrowth. Care plans are highly personalized to address the unique neurological and physical challenges faced by each individual living with this rare condition.

How is Megalencephaly Capillary Malformation Polymicrogyria Syndrome treated?

Because Megalencephaly Capillary Malformation Polymicrogyria Syndrome involves multiple organ systems, there is no standardized protocol. Instead, treatment focuses on symptom management. Physicians often prioritize the control of epilepsy, which affects a significant portion of patients, and the monitoring of progressive tissue overgrowth. In our DiseaseMaps community, 23 members have shared that coordination between specialists is the most effective way to manage the complex needs associated with Megalencephaly Capillary Malformation Polymicrogyria Syndrome.

Which specialists should be on the care team?

A comprehensive care team for those diagnosed with Megalencephaly Capillary Malformation Polymicrogyria Syndrome typically includes:

• Pediatric Neurologists: To manage seizures and monitor brain structural abnormalities like polymicrogyria.


• Geneticists: To oversee the PIK3CA-related spectrum disorder diagnosis and provide family counseling.


• Physical and Occupational Therapists: To assist with motor delays and developmental milestones.


• Dermatologists: To monitor and treat capillary malformations.


• Orthopedists: To address potential limb length discrepancies caused by localized overgrowth.

Are there medications for MCAP?

While no drug specifically treats the underlying genetic mutation of Megalencephaly Capillary Malformation Polymicrogyria Syndrome, anticonvulsants (such as levetiracetam or valproate) are commonly prescribed to manage seizures. Recent research into PIK3CA-inhibitors, such as alpelisib (Piqray), represents an emerging area of study for individuals with overgrowth syndromes, though their use in Megalencephaly Capillary Malformation Polymicrogyria Syndrome remains a subject of ongoing clinical investigation.

How does treatment effectiveness vary?

Treatment success in Megalencephaly Capillary Malformation Polymicrogyria Syndrome is highly variable. Because the genetic expression of the PIK3CA mutation can differ significantly between patients, the severity of neurological symptoms and physical overgrowth is not uniform. Regular screening and early intervention are essential to improving quality of life.

Next steps

• Consult a pediatric neurologist and a clinical geneticist to establish a baseline care plan.


• Join the DiseaseMaps.org community to connect with other families managing Megalencephaly Capillary Malformation Polymicrogyria Syndrome.


• Monitor for clinical trials on ClinicalTrials.gov regarding PIK3CA-related overgrowth syndromes.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice; please consult your primary care team regarding specific treatment decisions.

References

• NIH Genetic and Rare Diseases Information Center (GARD): MCAP Syndrome


• Orphanet: Megalencephaly-capillary malformation-polymicrogyria syndrome


• OMIM (Online Mendelian Inheritance in Man): #603387


• The PIK3CA-Related Overgrowth Spectrum (PROS) Patient Advocacy Groups